INDIANAPOLIS—Eli Lilly & Co. recently announced that it will create 100 new jobs here as a result of investing $400 million in manufacturing facilities at the company's Lilly Technology Center campus. The investments include enhancements to existing manufacturing facilities that make insulin, syringe filling, device assembly and packaging operations, as well as additional capacity for its growing portfolio of diabetes medicines and initial capital investments for future medicines.
The drug maker said its plans are a result of increased demand for its medicines and for the production of additional capacity for future medicines, and are helped by having more capital available as a result of tax reform.
"These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," says Myles O'Neill, president of manufacturing operations. "All of these projects support Lilly's investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics."
Lilly has invested over $5 billion in the United States since 2012, with the majority of this investment in its Indiana facilities and nearly $2 billion in manufacturing of diabetes medicines.